Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Επικοινωνία Submitted by Δημήτρης Σπάχος on Τετ, 12/02/2020 - 22:05
